Redx Pharma PLC
Macclesfield, GB· latest recorded location
Redx Pharma PLC is named on 27 US grants and 36 published applications in this corpus. Its most frequent classification is C07D (Heterocyclic compounds).
- Granted patents
- 27
- Published applications
- 36
- Inventors
- 52
- Granted in 2026 so far
- 1
- Most recent grant
- 28 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2012 | 1 | 1 |
| 2013 | 2 | 3 |
| 2014 | 3 | 2 |
| 2015 | 4 | 1 |
| 2016 | 0 | 1 |
| 2017 | 3 | 6 |
| 2018 | 1 | 2 |
| 2019 | 4 | 3 |
| 2020 | 2 | 1 |
| 2021 | 0 | 3 |
| 2022 | 2 | 0 |
| 2023 | 1 | 3 |
| 2024 | 1 | 5 |
| 2025 | 2 | 1 |
| 2026 | 1 | 4 |
By publication year. 2026 runs to 8 Oct.
Technology areas
Share of 63 documents
- C07DHeterocyclic compounds63
- A61PTherapeutic uses of medicines56
- A61KMedicines and medical preparations48
- C07CAcyclic or carbocyclic compounds10
- Y02PLow-carbon manufacturing8
- Y02ATechnologies for adaptation to climate change6
- C07BGeneral methods of organic chemistry4
- C07HSugars2
- C07JSteroids2
- A01NPreservation of bodies of humans or animals or plants or parts thereof1
Recent patents
- Phenyl- and pyridopyrazole derivatives as inhibitors of DDR128 Jul 2026US 12,692,247 B2
- Modulators of rho-associated protein kinase28 Oct 2025US 12,453,734 B2
- N-pyridinyl acetamide derivatives as inhibitors of the Wnt signaling pathway21 Jan 2025US 12,202,826 B2
- Modulators of Rho-associated protein kinase23 Jan 2024US 11,878,020 B2
- N-pyridinyl acetamide derivatives as inhibitors of the WNT signaling pathway9 May 2023US 11,643,408 B2
- Solid forms of a rock inhibitor19 Mar 2026US 2026/0078108 A1
- Ddr1 and ddr2 inhibitors for the treatement of cancer and fibrotic diseases12 Mar 2026US 2026/0069571 A1
- Pyrido-pyrazoles as inhibitors of ddr's for the treatment of fibrotic disorders and cancer26 Feb 2026US 2026/0055102 A1
- Modulators of rho-associated protein kinase5 Feb 2026US 2026/0034140 A1
- Modulators of rho-associated protein kinase17 Apr 2025US 2025/0122173 A1
Most cited
By later US patents
- Fused bicyclic (hetero)aromatic compounds useful for the treatment of cancers39US 10,183,939 B22019
- N-pyridinyl acetamide derivatives as inhibitors of the Wnt signaling pathway6US 10,047,079 B22018
- Use of rosuvastatin lactols as medicaments6US 9,102,656 B22015
- N-pyridinyl acetamide derivatives as Wnt signalling pathway inhibitors5US 10,202,375 B22019
- Substituted [1,2,4]triazolo[4,3-A]pyrazines for medicaments and pharmaceutical compositions4US 8,946,224 B22015